title: The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers.
abstract: GSK1322322 is the first in a new class of antibiotics that inhibit peptide deformylase, necessary for bacterial protein maturation. Previously, low absolute bioavailability was observed for the 1500-mg oral tablet formulation, resulting in a less than dose-proportional increase from the 1000-mg dose. Furthermore, high variability of pharmacokinetic (PK) parameters within cohorts was suggested to be associated with differences in body weight. This open-label, randomized, 4-period, crossover, single-dose phase I study in healthy individuals compared the PK, safety, and tolerability of free base oral tablets under fasted or fed conditions with intravenous and oral mesylate salt solution of GSK1322322 under fasted conditions. Absolute bioavailability of GSK1322322 1500-mg free base tablets under fasted conditions, fed conditions, and oral mesylate salt solution was 57%, 77%, and 92%, respectively. Moderate-fat/calorie food intake increased area under the concentration-time curve (AUC0-∞) by 36%, maintained maximum observed concentration (Cmax), and delayed time to Cmax. It appeared that AUC0-∞decreased with body weight, whereas clearance increased. GSK1322322 administration resulted in only mild-to-moderate adverse events. These results support future clinical investigations of the free base oral tablet formulation of GSK1322322 1500 mg after intake of a moderate-fat/calorie meal, including further investigation of a potential weight-based dosage change.
authors.affiliation: GlaxoSmithKline Research Triangle Park, NC, USA.
authors.forename: Odin
authors.initials: O
authors.lastname: Naderer
authors.affiliation: GlaxoSmithKline Research Triangle Park, NC, USA.
authors.forename: Lori S
authors.initials: LS
authors.lastname: Jones
authors.affiliation: GlaxoSmithKline Upper Merion, PA, USA.
authors.forename: John
authors.initials: J
authors.lastname: Zhu
authors.affiliation: GlaxoSmithKline Research Triangle Park, NC, USA.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Coffin
authors.affiliation: GlaxoSmithKline Upper Merion, PA, USA.
authors.forename: Milena
authors.initials: M
authors.lastname: Kurtinecz
authors.affiliation: GlaxoSmithKline Upper Providence, PA, USA.
authors.forename: Etienne
authors.initials: E
authors.lastname: Dumont
keywords: GSK1322322; free base; mesylate salt solution; peptide deformylase; pharmacokinetics